再発多発性骨髄腫に対するボルテゾミブ療法における副作用発現頻度と発現時期の調査

書誌事項

タイトル別名
  • Investigation of Adverse Drug Reactions in Bortezomib Therapy for Relapsed Multiple Myeloma

この論文をさがす

説明

Bortezomib was approved in 2006 for use in patients with multiple myeloma.Although a high frequency of adverse drug reactions (ADRs) was reported in some clinical studies on bortezomib,little information is available on the time of occurrence of the ADRs.Therefore,we investigated the ADRs in 15 patients with relapsed multiple myeloma who received bortezomib alone or combined with dexamethasone,for 2 cycles.The ADRs with high frequencies were constipation (80.0%),leucopenia (73.3%),anemia (73.3%),fatigue (73.3%),peripheral neuropathy (66.7%) and thrombocytopenia (66.7%).The number of leukocytes decreased to the minimum on the 9th day and had recovered on the 14th day.The number of platelets decreased to the minimum on the 13th day,and had recovered on the 19th day.Gastrointestinal adverse reactions including constipation,diarrhea,nausea and vomiting were observed from the 5th day.<br>Based on these results,we prepared a patient education sheet showing the times of occurrence of high frequency ADRs in the therapy schedule visually.This sheet should be useful in gaining the understanding of patients and their families regarding bortezomib therapy as well as enhancing its safety.

収録刊行物

  • 医療薬学

    医療薬学 36 (4), 270-276, 2010

    一般社団法人日本医療薬学会

参考文献 (9)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ